Psilocybin-assisted therapy for depression has moved from preliminary open-label studies into controlled Phase 2 trials, and — in the case of COMPASS Pathways' COMP360 program — into Phase 3. This piece summarizes what the peer-reviewed trial record actually shows, and what it doesn't, without overstating the current state of the evidence.
Carhart-Harris et al., NEJM 2021: Psilocybin vs. Escitalopram
Published in The New England Journal of Medicine in April 2021, this Phase 2 trial randomized adults with moderate-to-severe major depressive disorder to either two 25 mg doses of psilocybin with psychological support, or six weeks of daily escitalopram (an SSRI). The primary endpoint was change on the QIDS-SR-16 depression scale. On that primary measure, the difference between groups was not statistically significant. Several secondary endpoints favored psilocybin, but the trial was not designed to establish superiority on those measures. The correct read is: psilocybin performed at least comparably to a standard SSRI in this small controlled sample, but the trial did not establish superiority.
Davis et al., JAMA Psychiatry 2021: Psilocybin-Assisted Therapy in MDD
Published in JAMA Psychiatry in November 2020 (with print in 2021), this randomized trial from Johns Hopkins compared immediate versus delayed psilocybin-assisted therapy in 24 adults with major depressive disorder. The immediate-treatment group showed large and rapid reductions in depression severity on the GRID-HAMD, with effects sustained at four-week follow-up. The signal was strong; the sample was small; and the comparator was a waitlist, not an active treatment. This is best read as a promising early-phase result that requires confirmation in larger, actively-controlled trials.
Carhart-Harris 2016: The Original Open-Label Signal
The clinical evidence base did not start with the 2021 papers. Carhart-Harris and colleagues published an open-label feasibility study in The Lancet Psychiatry in 2016 with 12 patients with treatment-resistant depression. All 12 showed reductions in depressive symptoms at one week, and the majority maintained clinically meaningful improvement at three months. The study had no control arm and cannot establish efficacy on its own, but it was the signal that opened the door to the controlled trials that followed.
COMPASS Pathways: Phase 3 Underway
COMPASS Pathways' COMP360 (a proprietary synthetic psilocybin) has advanced to Phase 3 trials in treatment-resistant depression, following Phase 2b results (Goodwin et al., NEJM 2022) that showed a statistically significant reduction in MADRS score at three weeks after a single 25 mg dose versus a 1 mg comparator. Pivotal Phase 3 data will determine whether a psilocybin therapy becomes eligible for FDA approval in this indication. Approval would also require DEA scheduling action on the specific formulation.
Safety Signal in the Trial Data
Across the controlled psilocybin trials, serious adverse events have been uncommon. The most frequently reported adverse events during the acute session are headache, nausea, and transient anxiety. There is a low but non-zero rate of suicidal ideation reported in some arms — a signal the field is watching closely, and one of the reasons Phase 3 data on benefit-risk in unstable patient populations matters.
What the Evidence Supports — and What It Doesn't
Read together, the current trial record supports a genuine and reproducible acute antidepressant signal from a single or small number of high-dose psilocybin sessions paired with psychological support, in adults with depression. It does not yet support strong claims about long-term efficacy, durability at population scale, or superiority to existing treatments. Phase 3 readouts over the next several years will decide those questions.
The Dose-Response Signal
Across the COMPASS Phase 2b data and related Phase 2 work, a dose-response pattern is visible: a single 25 mg dose of synthetic psilocybin produced significantly greater MADRS reductions than a 10 mg dose, which in turn produced greater reductions than a 1 mg active-comparator dose. Dose-response is one of the strongest signals a drug candidate can produce, because it argues against pure placebo effect and toward a real pharmacological contribution. It is not by itself proof of clinical efficacy at Phase 3 scale, but it is a meaningful piece of the evidentiary case.
The Unblinding Problem, in Psilocybin Specifically
Every psychedelic trial confronts functional unblinding — the participant knows whether they received an active dose because the subjective experience is unmistakable. In the psilocybin trials, unblinding is addressed with an active-comparator arm (a low dose of psilocybin itself, not inert placebo) rather than eliminated. This partially controls expectation effects, but it does not fully resolve them, and any read of Phase 3 psilocybin data will have to account for this. The critical question — which the field has not fully answered — is how much of the reported clinical effect survives once expectation is properly controlled for.
How to Read a Trial Result
When Phase 3 readouts land, three questions matter more than any headline. First: what was the pre-specified primary endpoint, and did it hit? Secondary endpoints are informative but not confirmatory. Second: what was the effect size versus the active comparator, not versus untreated baseline? Baseline-to-post comparisons overstate real drug effect. Third: what is the durability curve — does the effect persist to 12 weeks, 6 months, 12 months? A single-session therapy has to demonstrate durability to justify a distinct clinical role. Reading psilocybin Phase 3 data through those three lenses will be a better guide than reading whichever press release moves the stock.
A Brief Note on Sanctuary Tulum
Sanctuary Tulum works with psilocybin in a licensed, physician-supervised setting in Tulum, Mexico, operating since 2011. For our clinical framework, see our psilocybin therapy and safety credentials pages.
References
- Carhart-Harris R, Giribaldi B, Watts R, et al. "Trial of psilocybin versus escitalopram for depression." N Engl J Med. 2021;384(15):1402–1411.
- Davis AK, Barrett FS, May DG, et al. "Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial." JAMA Psychiatry. 2021;78(5):481–489.
- Goodwin GM, Aaronson ST, Alvarez O, et al. "Single-dose psilocybin for a treatment-resistant episode of major depression." N Engl J Med. 2022;387(18):1637–1648.
- Carhart-Harris RL, Bolstridge M, Rucker J, et al. "Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study." Lancet Psychiatry. 2016;3(7):619–627.
- US Food & Drug Administration. Breakthrough Therapy Designation program overview.
